Lumason in Stress Echocardiography for CAD Diagnosis

Phase 3, open-label, single-arm trial of sulfur hexafluoride in coronary artery disease (CAD), sponsored by Bracco Diagnostics Inc. Primary endpoints: Sensitivity and Specificity for Detection or Exclusion of Coronary Artery Disease (CAD) at 6 months and Reader-Specific Percentages of Participants Identified as Having a Critical Shift From Suboptimal to Optimal Echocardiographic Images at 6 months. Started Sep 2015; status: completed.